// App-Quantinova.ai

: Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Researchers

Presenter

  • Edoardo Pennesi

Principal Investigators

  • Anneke C.J. Ammerlaan

  • Yilin Jiang

  • Vincent H.J. van der Velden

  • Berna Beverloo

  • Barbara Sleight

  • Susana Rives

  • Cristina Diaz de Heredia Rubio

  • Francisco J. Bautista Sirvent

  • Alba Rubio-San-Simón

  • Fanny Rialland

  • Carmelo Rizzari

  • Bella Bielorai

  • Arnaud Petit

  • Benedicte Bruno

  • Ingrid Øra

  • Anna Nilsson

  • Gernot Engstler

  • Claudia Rossig

  • Benoit Brethon

  • Franco Locatelli

  • Christian M. Zwaan

Medical Centers

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

  • Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • IRCCS Ospedale Pediatrico Bambino Gesú, Catholic University of the Sacred Heart, Rome, Italy

  • Pediatric Hematology-Oncology Unit, University of Milano-Bicocca, MBBM Foundation, San Gerardo Hospital, Monza, Italy

  • DEPARTMENT OF CLINICAL GENETICS, ERASMUS MC, Rotterdam, Netherlands

  • Division of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, Israel

  • Department of Pediatric Hematology and Immunology, Robert-Debré Hospital, AP-HP, University of Paris, Paris, France

  • Department of Pediatric Oncology and Hematology, Hospital Niño Jesús, Madrid, Spain

  • Pediatric Hematology, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France

  • Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany

  • Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France

  • St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria

  • Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain

  • Department of Immunology, Erasmus Medical Center, University Medical Center, Rotterdam, Netherlands

  • Pediatric Oncology and Hematology, Karolinska University Hospital, Stockholm, Sweden

  • department of pediatric Hematology and Oncology, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France

  • Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

Locations

  • Netherlands

  • Germany

  • United States

  • Israel

  • Spain

  • Sweden

  • France

  • Italy

  • Austria

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved